The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Open accessAbstract
Background Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment.Methods Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period.Results Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).Conclusions These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's half-life in the body is ;2 h (Autry et al., 2011), yet a single low-dose treatment elicits sustained (.1 week) antidepressant effects in patients (Berman et al., 2000;Zarate et al., 2006;Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Price et al., 2009
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ketamine rapidly induces flexibility in implicit representations of self on the Implicit Association Test 134,135 , and these shifts correlated with self-reported symptom improvements 110 , suggesting that ketamine can immediately impact the structure of implicit mental representations relevant to one's concept of self, a core form of cognitive bias in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [135]
In the citing paper
“Critically, several versions of the IAT have also been incorporated into clinical ketamine trials, which found that the “escape” version of the IAT (instead of “death,” the participant links the self with “escape” or “stay”) was associated with reductions in SI (57, 58).”
From New methods for assessing rapid changes in suicide risk (2021) · cites this paper as [57]
In the citing paper
“Administration of glutamate receptor antagonists, such as the NMDA antagonist, ketamine, have potent antidepressant effects especially in treatment resistant depressed patients”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Price et al., 2009
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [152]
In the citing paper
“Ketamine has been also shown to induce a rapid amelioration of suicidal ideation in major depressed patients 23, 24”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Measuring individual differences in implicit cognition: the implicit association test
Greenwald, A. G., McGhee, D. E., & Schwartz, J. L. K. (1998) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.74.6.1464 · Cited by 9,210
Understanding and using the Implicit Association Test: I. An improved scoring algorithm.
Greenwald, A. G., Nosek, B. A., & Banaji, M. R. (2003) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.85.2.197 · Cited by 5,815
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationUnderstanding and using the Implicit Association Test: III. Meta-analysis of predictive validity.
Greenwald, A. G., Poehlman, T. A., Uhlmann, E. L., & Banaji, M. R. (2009) · Journal of Personality and Social Psychology · doi:10.1037/a0015575 · Cited by 3,257
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Understanding and Using the Implicit Association Test: II. Method Variables and Construct Validity
Nosek, B. A., Greenwald, A. G., & Banaji, M. R. (2004) · Personality and Social Psychology Bulletin · doi:10.1177/0146167204271418 · Cited by 1,216
Cited by
Sorted by citations
Items 401–500 of 601
Howe, T., Blockeel, A. J., Taylor, H., Jones, M. W., Bazhenov, M., & Malerba, P. (2020) · Hippocampus · doi:10.1002/hipo.23276 · Cited by 9
Price, R. B., Panny, B., Degutis, M., & Griffo, A. (2020) · Journal of Abnormal Psychology · doi:10.1037/abn0000651 · Cited by 10
Self-citationBDNF Genetic Variant and Its Genotypic Fluctuation in Major Depressive Disorder
Fratelli, C. F., Siqueira, J. W. S., Gontijo, B. R., dos Santos, M. L., Silva, C. M. D. S., & da Silva, I. C. R. (2021) · Behavioural Neurology · doi:10.1155/2021/7117613 · Cited by 9
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
Aligeti, S., Quinones, M. P., & Salazar, R. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000146 · Cited by 9
A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry
Andrade, C., & Rao, T. S. (2017) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_345_17 · Cited by 9
Shivanekar, S., Gopalan, P., Pizon, A., Spotts, C., Cruz, N., Lightfoot, M., Rohac, R., Baumeister, A., Griffo, A., Panny, B., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192113792 · Cited by 8
Self-citationNew perspectives on glutamate receptor antagonists as antidepressants
Chung, C. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0400-8 · Cited by 8
Traditional Chinese Medicine Jiuwei Zhenxin Granules in Treating Depression: An Overview
Wang, J., & Wu, X. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s273324 · Cited by 9
Jordan, W., Siegel, R., Kumar, R., & Javitt, J. C. (2023) · International Journal of Toxicology · doi:10.1177/10915818231176971 · Cited by 8
Lamontagne, S. J., Gilbert, J. R., Zabala, P. K., Waldman, L. R., Zarate, C. A., & Ballard, E. D. (2023) · Psychological Medicine · doi:10.1017/s0033291723003331 · Cited by 8
Novel Therapeutic Targets for Major Depressive Disorder
Lazar, M. A., & McIntyre, R. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00034-2 · Cited by 9
Lamontagne, S. J., Ballard, E. D., & Zarate, C. A. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100450 · Cited by 10
Are suicide risk scales sensitive to change? A scoping review
Riblet, N. B. V., Matsunaga, S., Shiner, B. R., Schnurr, P. P., & Watts, B. V. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.007 · Cited by 11
Inflammation in Suicidality: Implications for Novel Treatment Options
Janelidze, S., & Brundin, L. (2013) · Modern trends in psychiatry · doi:10.1159/000346085 · Cited by 8
Szabo, S. T., Kilts, J. D., Naylor, J. C., Youssef, N. A., Strauss, J. L., Morey, R. A., Brancu, M., Hamer, R. M., Bradford, D. W., VA Mid-Atlantic MIRECC Work Group, et al. (2014) · Military Medicine · doi:10.7205/milmed-d-13-00337 · Cited by 8
Landrigan, J., Shawaf, F., Dwyer, Z., Abizaid, A. B., & Hayley, S. P. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.08.015 · Cited by 8
Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
Bera, K., Looger, L. L., Proekt, A., & Cichon, J. (2025) · The Neuroscientist · doi:10.1177/10738584251403946 · Cited by 9
Douleur morale, douleur physique : mécanismes neurobiologiques et traitement
Gaillard, A. (2014) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2014.01.015 · Cited by 7
La kétamine dans le traitement du trouble dépressif aigu sévère
Brittner, M., Micoulaud‐Franchi, J., Richieri, R. M., Boyer, L., Adida, M., Lançon, C., & Fond, G. B. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2013.11.013 · Cited by 7
Do we need pharmacogenetics to personalize antidepressant therapy?
Lanni, C., Racchi, M., & Govoni, S. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1237-5 · Cited by 7
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 1
Electrophysiological phenotypes of suicidality predict prolonged response to oral ketamine treatment
Can, A., Schwenn, P., Isbel, B., Beaudequin, D. A., Bouças, A. P., Dutton, M., Jones, M., Gallay, C. C., Forsyth, G., Bennett, M. R., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110701 · Cited by 8
Sufka, K. J., & White, S. W. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.013 · Cited by 7
Cabrera-Mendoza, B., Martínez-Magaña, J., Monroy-Jaramillo, N., Genis-Mendoza, A., Fresno, C., Fries, G., Walss-Bass, C., López-Armenta, M., García-Dolores, F., Díaz-Otañez, C., et al. (2021) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32830 · Cited by 8
Philipp-Muller, A. E., Reshetukha, T., Vázquez, G. H., Milev, R. V., Armstrong, D., Jagayat, J., & Alavi, N. (2021) · JMIR Research Protocols · doi:10.2196/30334 · Cited by 7
Weleff, J., Bryant, K. A., Kovacevich, A., & Barnett, B. S. (2022) · Case Reports in Psychiatry · doi:10.1155/2022/1104668 · Cited by 7
Wang, Y., Xu, J., Zhou, X., Che, L., Qiu, M., Liu, Y., Gao, M., & Yang, Z. (2025) · Advanced Science · doi:10.1002/advs.202516024 · Cited by 9
Le, G. H., Wong, S., Johnson, D. E., Lu, A., Orsini, D. K., Chisamore, N., Luch, S. D. D., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121081 · Cited by 6
Ketamine Evolving Clinical Roles and Potential Effects with Cognitive, Motor and Driving Ability
Edinoff, A. N., Sall, S., Koontz, C., Williams, A. K., Drumgo, D., Mouhaffel, A., Cornett, E. M., Murnane, K. S., & Kaye, A. D. (2023) · Neurology International · doi:10.3390/neurolint15010023 · Cited by 6
Gold, N. D., Mallard, A. J., Hermann, J. C., Zeifman, R. J., Pagni, B. A., Bogenschutz, M. P., & Ross, S. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0604 · Cited by 6
Jelovac, A., McCaffrey, C., Terao, M., Shanahan, E., Mohamed, E., Whooley, E., McDonagh, K., McDonogh, S., Igoe, A., Loughran, O., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05365-9 · Cited by 5
Nist, A. N., Walsh, S. J., & Shahan, T. A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06514-4 · Cited by 6
Barnett, B. S. (2024) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000766 · Cited by 6
Gergues, M. M., Lalani, L. K., & Kheirbek, M. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01942-y · Cited by 6
Kétamine et dépression : vers de nouvelles perspectives thérapeutiques en soins de support ?
Lemaire, A., Plançon, M., & Bubrovszky, M. (2014) · Psycho-Oncologie · doi:10.1007/s11839-014-0453-7 · Cited by 6
“Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?”
Soleimani, L., Welch, A. K., & Murrough, J. W. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0065-2 · Cited by 6
The interactive effects of ketamine and magnesium upon depressive-like pathology
Hayley, S. P., Razmjou, S., Litteljohn, D., Rudyk, C., Syed, S., Clarke, M., Pentz, R., & Dwyer, Z. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111131 · Cited by 6
Ketamine and Depression: A Review
Ryan, W. C., Marta, C. J., & Koek, R. J. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.40 · Cited by 6
Beaudequin, D. A., Can, A., Jones, M., Yang, C., Scherman, J. K., Dutton, M., Schwenn, P., Gallay, C. C., Jensen, E., Hermens, D. F., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114212 · Cited by 6
Higa, K. K., Ji, B., Buell, M. R., Risbrough, V. B., Powell, S. B., Young, J. W., Geyer, M. A., & Zhou, X. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv063 · Cited by 6
Rani, S., Yadav, S., & Ghorai, S. M. (2023) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822262191231024081805 · Cited by 5
Sonmez, A. I., Webler, R. D., Krueger, A. M., Godoy-Henderson, C., Sullivan, C. R. P., Wilson, S., Olsen, S. T., Schmid, S. P., Herman, A., Widge, A. S., et al. (2024) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2024.100073 · Cited by 5
Ji, I. S., Cheng, M. C. H., Teopiz, K. M., Dri, C. E., Wong, S., Le, G. H., Rhee, T. G., Guillen-Burgos, H. F., Lo, H. K. Y., Zheng, Y. J., et al. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.10.056 · Cited by 6
Inflammation and treatment strategies for suicidal behavior
Behera, C., Gupta, S., Shelton, R. C., & Dwivedi, Y. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2659772 · Cited by 5
Chaudhary, P., Shah, P., & Mehta, P. (2022) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_231_21 · Cited by 5
Making Ketamine Work in the Long Run
Associates, I. P., & Early, T. S. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.141 · Cited by 5
Douleur psychique : un symptôme ?
Raphaël Gaillard, B., Löo, H., & Olié, J. (2010) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32300-3 · Cited by 5
The implicit suicidal mind clings to life
Harrison, D. P., Stritzke, W. G. K., Leong, J. Y. S., Ellison, T. M., Fay, N., & Hudaib, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814297-4.00002-9 · Cited by 5
Orser, B. A. (2021) · Anesthesiology · doi:10.1097/aln.0000000000003798 · Cited by 5
Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology
Moroz, M., & Carhart-Harris, R. L. (2018) · doi:10.1109/var4good.2018.8576882 · Cited by 6
Infusing Hope Into the Treatment of Suicidality: a Review of Ketamine’s Effects on Suicidality
Rengasamy, M. L., Hsiung, K. S., & Price, R. B. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00184-3 · Cited by 5
Self-citationGillespie, C. F., Szabo, S. T., & Nemeroff, C. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00036-9 · Cited by 6
Ritter, P. S., Bauer, M., & Pilhatsch, M. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4132-5 · Cited by 4
Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies
Averill, L. A., Murrough, J. W., & Abdallah, C. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_7 · Cited by 5
Pochwat, B. (2021) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/134330 · Cited by 4
Rawal, B., Rančić, V., & Ballanyi, K. (2022) · Brain Sciences · doi:10.3390/brainsci12050651 · Cited by 6
A feasibility study of low‐dose ketamine for acute management of suicidal ideation
Gaither, R., Ranney, M. L., Peachey, A. M., Burock, J., Rogers, J., Bucci, L., & Beaudoin, F. L. (2022) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12790 · Cited by 5
Ketamine in treatment-resistant depression
Lapidus, K. A. B., & Mathew, S. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.027 · Cited by 4
Self-citationThe development of an implicit association test for measuring forgiveness.
Goldring, J. (2011) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 4
Ketamine for unipolar depression: A systematic review of efficacy and safety
Peiris, T. E., Pokhrel, A., & Paudel, Y. (2025) · Australasian Psychiatry · doi:10.1177/10398562251328805 · Cited by 3
Overcoming Antidepressant Treatment Resistance: Focus on Glutamate
Murrough, J. W., & Mathew, S. J. (2010) · Modern trends in psychiatry · doi:10.1159/000319509 · Cited by 3
Self-citationScuteri, D., Tonin, P., Corasaniti, M. T., & Bagetta, G. (2022) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2203133 · Cited by 3
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 4
Inflammation and Suicidal Behavior
Postolache, T. T., Manalai, P., Brenner, L. A., & Brundin, L. (2015) · Advances in biological psychiatry · doi:10.1159/000434746 · Cited by 3
Antidepressants and Suicide Risk: Harmful or Useful?
Courtet, P., Nobile, B., & López‐Castromán, J. (2017) · Springer eBooks · doi:10.1007/978-981-10-4816-6_18 · Cited by 4
Sex Differences in the Antidepressant Effects of Ketamine in Animal Models of Depression
Adu‐Nti, F., George, G.-K., & Benjamin, A. (2019) · International Journal of Depression and Anxiety · doi:10.23937/2643-4059/1710013 · Cited by 3
Quiroz, J. A., Chen, G., Drevets, W. C., Henter, I. D., & Manji, H. K. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.004 · Cited by 3
BDNF and Synaptic Plasticity: The Recent Cell Biology for Understanding of Brain Disorders
Mizui, T. (2013) · Clinical Pharmacology & Biopharmaceutics · doi:10.4172/2167-065x.s1-004 · Cited by 3
Toward Better Animal Models for Molecular Psychiatry
Monteggia, L. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.019 · Cited by 3
Ballard, E. D., & Price, R. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_4 · Cited by 3
Self-citationEken, H. N., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02564-y · Cited by 2
Self-citationKétamine, dépression et suicide : vers une nouvelle classe d’antidépresseurs ?
Moirand, R., Iceta, S., & Poulet, E. (2015) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2015.10.022 · Cited by 2
The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression
Molero, P., Aubá, E., Unceta, M. D. M., & Pedreño, F. O. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_11 · Cited by 2
Maraone, A., Trebbastoni, A., Vita, A. D., D’Antonio, F., de Lena, C., & Pasquini, M. (2023) · JMIR Research Protocols · doi:10.2196/39223 · Cited by 2
Intranasal Delivery of Ketamine Induces Cortical Disinhibition
Qiao, X., Grieco, S. F., Yu, Z., Holmes, T. C., & Xu, X. (2023) · eNeuro · doi:10.1523/eneuro.0107-23.2023 · Cited by 2
Mattis, P. J., Gopin, C. B., & Mirra, K. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3106-0_23 · Cited by 2
Ketamine as a Rapid Antidepressant
Cusin, C. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_10 · Cited by 2
Ist eine Aktivierung von Mikrogliazellen von pathophysiologischer Bedeutung?
Gos, T., Handerer, I., Bernstein, H., Bogerts, B., & Steiner, J. H. (2014) · Nervenheilkunde · doi:10.1055/s-0038-1627742 · Cited by 2
The promise of rapidly acting antidepressants: challenges and opportunities.
Smith, M. A., & Pathak, S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.033 · Cited by 2
Intérêts de la kétamine : de l’effet antidépresseur à l’effet anti-suicide ?
Laforgue, E., Sauvaget, A., Bulteau, S., & Vanelle, J. (2016) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2015.12.007 · Cited by 2
Ketamine Treatment for Major Depression
Anand, A., Mathew, S. J., & Janicak, P. G. (2011) · Psychopharm Review · doi:10.1097/01.psyphr.0000410133.47951.30 · Cited by 2
Self-citationS-ketamine for the treatment of depression
Järventausta, K., Kampman, O., Yli‐Hankala, A., & Leinonen, E. V. J. (2015) · Cited by 2
Falcone, T., Staniskyte, M., Forcén, F. E., & Vengoechea, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-74391-2_1 · Cited by 3
Distinct Roles of NMDA Receptor GluN2 Subunits in the Effects of Ketamine and Its Enantiomers
Ide, S., & Ikeda, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_10 · Cited by 2
Kalkman, H. O. (2021) · Psychiatry International · doi:10.3390/psychiatryint2010008 · Cited by 2
Immune System Related Markers: Changes in childhood Neuropsychiatry Disorders Cause and Consequence
Falcone, T., & Franco, K. S. N. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_9 · Cited by 2
Coplan, J. D., Gupta, N. K., Flynn, S. K., Reiner, W. J., Gaita, D. J., Fulton, S. L., Rozenboym, A. V., Tang, J. E., Cooper, T. B., & Mann, J. J. (2018) · Chronic Stress · doi:10.1177/2470547018785625 · Cited by 2
Editorial (Thematic Selection: Inflammatory and Immune Responses in Depression)
Sharma, A. (2016) · Current Neuropharmacology · doi:10.2174/1570159x1407160826191654 · Cited by 2
Robson, M. J. (2013) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.3661 · Cited by 2
Molecular and functional properties of PFC astrocytes during neuroinflammation-induced anhedoniaPreprint
Castro, B. D., Bernstein, A. M., Coppola, G., Sofroniew, M. V., & Khakh, B. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.27.424483 · Cited by 2
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Novel Targets for Drug Treatment in Psychiatry
Kurita, M., García‐Bea, A., & González‐Maeso, J. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_30 · Cited by 1
Talaeı, A., Hoseini, F. F., Mahdavi, M., Salehi, M., Karimani, A., & Afzaljavan, F. (2023) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v18i4.13627 · Cited by 1
Vieira, F., Caliman‐Fontes, A. T., Souza‐Marques, B., Faria-Guimarães, D., Lins-Silva, D. H., Santos‐Lima, C., Jesus‐Nunes, A. P., & Quarantini, L. C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116443 · Cited by 1
Choi, H., Le, G. H., Teopiz, K. M., Mansur, R. B., Rosenblat, J. D., Wong, S., Byun, S., & McIntyre, R. S. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251338262 · Cited by 1
Managing the risk of suicide in people with treatment-resistant depression
Franz, P. J., & Alpert, J. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00039-6 · Cited by 1
Manza, P., Belcher, A. M., Fitzsimons, H., Spaderna, M., Greenblatt, A. D., Smith, H. C., Derenoncourt, M., Gann, D. S., Farooq, U., Kvarta, M. D., et al. (2025) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2025.2541212 · Cited by 1
Strous, J. F. M., Roelandt, G. H. J., van Dalfsen, J. H., Kamphuis, J., Marijnissen, R. M., & Schoevers, R. A. (2025) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.70044 · Cited by 1
Roelandt, G. H. J., Strous, J. F. M., Marijnissen, R. M., Kamphuis, J., van Dalfsen, J. H., & Schoevers, R. A. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116909 · Cited by 1
Metadata
- Authors
- Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Harvard University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Price, Rebecca B.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 66
- Issue
- 5
- Pages
- 522-526
- ISSN
- 0006-3223 (ISSN-L)
- PMC
- PMC2935847
- OpenAlex
- W2118815581
- Cited by
- 600
- References
- 22
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 18 · 2023: 25 · 2022: 43 · 2021: 49 · 2020: 43 · 2019: 39 · 2018: 31 · 2017: 34 · 2016: 46 · 2015: 62 · 2014: 45 · 2013: 42 · 2012: 43
- FWCI
- 21.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (F31 MH081468, K23-MH-069656, MO1-RR-00071)
- National Alliance for Research on Schizophrenia and Depression
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- intravenous ketamine, treatment-resistant depression, suicidality, suicide risk, Implicit Association Test, rapid antidepressant effects, suicide assessment
- MeSH terms
- Suicide Prevention, Depression, Drug Resistance, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Suicide, Cohort Studies, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
